2022年度小细胞肺癌治疗进展

Annual progress in the treatment of small cell lung cancer in 2022

小细胞肺癌(small cell lung cancer,SCLC)作为一种神经内分泌肿瘤,具有侵袭性强、预后差等特点。长期以来,SCLC的治疗方式有限,依托泊苷联合铂类化疗仍然是广泛期SCLC标准一线治疗的基础。尽管初期对放化疗敏感,但大部分患者易在短时间内复发或耐药,5年生存率极低。免疫治疗药物的出现打破了SCLC治疗的瓶颈,免疫检查点抑制剂提高了SCLC患者的生存率;在探索SCLC二线及后线治疗过程中,δ样配体3特异性双抗、多腺苷二磷酸核糖聚合酶(poly ADP ribose polymerase,PARP)抑制剂逐渐崭露头角,为SCLC后线治疗带来新的进步。本文将盘点2022年度SCLC治疗的临床进展。

Small cell lung cancer(SCLC)is a kind of malignant tumor with strong invasiveness and poor prognosis.Treatment options for SCLC have been stalled for a long time,and etoposide combined with platinum chemotherapy is still the basis of standard first-line treatment for extensive stage SCLC.Despite its initial sensitivity to chemotherapy and radiotherapy,almost all patients will subsequently relapse and resistance,and the 5-year survival rate mains dismal.New opportunities have emerged in recent years due to the development immunotherapeutic drugs and have helped patients achieve long-term benefits.In the process of exploring salvage treatment of SCLC,delta-like ligand 3 inhibitors and poly ADP ribose polymerase(PARP)inhibitors gradually emerged,bringing new breakthroughs for post-line treatment of SCLC.This article aimed to review the clinical progresses in the treatment of SCLC in 2022.